logo-loader
view712 North

712 North excited to be funded by the National Institute of Health

712 North CEO Marcel V. Alavi spoke with Proactive at the Bio Investor Forum in San Francisco. 
Privately-held 712 North is an early-stage biotech developing personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Salt Lake Potash welcomes key new strategic investor as part of A$15mln funding

Salt Lake Potash Ltd's (ASX:SO4) Tony Swiericzuk speaks to Proactive after announcing a A$10 million strategic investment from Equatorial Resources Ltd (ASX:EQX) as part of a A$15 million placement of convertible notes to corporate and institutional investors. Salt Lake is in the final stages of...

11 hours, 55 minutes ago

2 min read